Investor Logos Global Management LP
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Logos Global Management LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-08-22 13D/A ARVN / Arvinas, Inc. 4,800,000 6,300,000
2025-08-14 13G ERAS / Erasca, Inc. 15,100,000
2025-08-14 13G/A CBIO / Crescent Biopharma, Inc. 575,000
2025-08-14 13G/A PRTA / Prothena Corporation plc 2,950,000 0
2025-08-14 13G/A ANNX / Annexon, Inc. 6,600,000 0
2025-07-28 13G VSTM / Verastem, Inc. 3,425,000
2025-06-16 13D ARVN / Arvinas, Inc. 4,800,000
2025-06-04 13G PRTA / Prothena Corporation plc 2,950,000
2025-05-13 13D/A OLMA / Olema Pharmaceuticals, Inc. 3,248,818 3,208,875
2025-04-28 13G ANNX / Annexon, Inc. 2,900,000 6,600,000
2025-02-14 13G/A NXTC / NextCure, Inc. 2,500,000 0
2025-02-14 13G/A ELEV / Elevation Oncology, Inc. 3,500,000 0
2024-11-27 13G GLYC / GlycoMimetics, Inc. 5,000,000
2024-11-14 13G/A UNCY / Unicycive Therapeutics, Inc. 3,469,927 5,078,927
2024-11-14 13G/A ELEV / Elevation Oncology, Inc. 3,650,000 3,500,000
2024-11-14 13G/A NXTC / NextCure, Inc. 2,000,460 2,500,000
2024-11-14 13G/A CYBN / Cybin Inc. 40,000,000 0
2024-11-14 13G/A ATYR / aTyr Pharma, Inc. 5,800,000 1,750,000
2024-11-14 13G/A ANNX / Annexon, Inc. 6,944,444 2,900,000
2024-11-14 13G/A ADVM / Adverum Biotechnologies, Inc. 15,000,000 416,666
2024-10-23 13G DRUG / Bright Minds Biosciences Inc. 100,000
2024-08-27 13G CYBN / Cybin Inc. 40,000,000
2024-08-13 13D/A DSGN / Design Therapeutics, Inc. 2,812,501 4,232,627
2024-06-06 13D/A OLMA / Olema Pharmaceuticals, Inc. 4,266,948 3,248,818
2024-04-01 13G NXTC / NextCure, Inc. 2,000,460
2024-02-22 13G ADVM / Adverum Biotechnologies, Inc. 15,000,000
2024-02-14 13G/A ALLK / Allakos Inc. 5,286,666 2,900,000
2024-02-14 13G/A SYRE / Spyre Therapeutics, Inc. 150,000
2024-02-13 13G/A ANNX / Annexon, Inc. 3,100,000 6,944,444
2024-02-13 13G/A IDYA / IDEAYA Biosciences, Inc. 3,900,000 1,800,000
2024-01-22 13G ELEV / Elevation Oncology, Inc. 3,650,000
2024-01-22 13G UNCY / Unicycive Therapeutics, Inc. 3,469,927
2024-01-02 13G ATYR / aTyr Pharma, Inc. 5,800,000
2023-11-28 13D/A OLMA / Olema Pharmaceuticals, Inc. 3,758,818 4,266,948
2023-07-18 13G AGLE / Aeglea BioTherapeutics Inc 6,350,000
2023-06-22 13G ANNX / Annexon, Inc. 3,100,000
2023-02-14 13G/A BCYC / Bicycle Therapeutics plc - Depositary Receipt (Common Stock) 1,550,000 1,435,000
2023-02-14 13G/A IDYA / IDEAYA Biosciences, Inc. 3,900,000
2023-02-14 13G/A ALLK / Allakos Inc. 5,936,666 5,286,666
2023-02-14 13G/A DYN / Dyne Therapeutics, Inc. 2,954,392 2,150,000
2022-09-28 13G ALLK / Allakos Inc. 5,936,666
2022-05-02 13G BCYC / Bicycle Therapeutics plc - Depositary Receipt (Common Stock) 870,000 1,550,000
2022-03-31 13D DSGN / Design Therapeutics, Inc. 2,812,501
2022-03-18 13G HARP / Harpoon Therapeutics, Inc. 1,500,000 2,650,000
2022-02-14 13G/A HARP / Harpoon Therapeutics, Inc. 1,830,000 1,500,000
2022-02-14 13G/A ALGS / Aligos Therapeutics, Inc. 2,872,785 0
2022-02-14 13G/A DYNE / Dyntek Inc 3,894,392 2,954,392
2022-02-14 13G/A BCYC / Bicycle Therapeutics plc - Depositary Receipt (Common Stock) 1,500,000 870,000
2022-02-14 13G/A KZR / Kezar Life Sciences, Inc. 2,500,000 1,450,000
2022-02-14 13G/A VRDN / Viridian Therapeutics, Inc. 1,495,000 0
2022-02-14 13G/A COGT / Cogent Biosciences, Inc. 1,907,971 150,000
2022-02-14 13G/A NKTX / Nkarta, Inc. 1,927,180 0
2022-01-26 13G/A ELDN / Eledon Pharmaceuticals, Inc. 1,339,793 0
2021-12-27 13G HARP / Harpoon Therapeutics, Inc. 1,830,000
2021-12-02 13G CMPS / COMPASS Pathways plc - Depositary Receipt (Common Stock) 1,400,000
2021-11-15 13G BCEL / Atreca, Inc. 996,584
2021-09-29 13G/A VRDN / Viridian Therapeutics, Inc. 550,000 1,495,000
2021-09-13 13G FBRX / Forte Biosciences, Inc. 0
2021-09-09 13G/A ELDN / Eledon Pharmaceuticals, Inc. 1,339,793
2021-08-16 13G DYNE / Dyntek Inc 3,894,392
2021-08-13 13G ALGS / Aligos Therapeutics, Inc. 2,872,785
2021-07-29 13G BCYC / Bicycle Therapeutics plc - Depositary Receipt (Common Stock) 1,500,000 1,500,000
2021-07-29 13G KZR / Kezar Life Sciences, Inc. 2,500,000 2,500,000
2021-06-15 13D/A ALXO / ALX Oncology Holdings Inc. 3,080,901 3,156,981
2020-12-03 13D OLMA / Olema Pharmaceuticals, Inc. 3,758,818
2020-11-19 13G/A COGT / Cogent Biosciences, Inc. 1,928,291 1,907,971
2020-11-16 13G/A VRDN / Viridian Therapeutics, Inc. 6,000,000 550,000
2020-11-09 13G 88907J107 / Novus Therapeutics, Inc. 224,071
2020-11-09 13G VRDN / Viridian Therapeutics, Inc. 6,000,000
2020-10-22 13G CLDX / Celldex Therapeutics, Inc. 1,700,000
2020-09-08 13G COGT / Cogent Biosciences, Inc. 1,928,291
2020-09-01 13G NKTX / Nkarta, Inc. 1,927,180
2020-08-31 13G KROS / Keros Therapeutics, Inc. 1,350,000
2020-08-26 13D ALXO / ALX Oncology Holdings Inc. 3,080,901 3,080,901
2020-08-25 13D ALXO / ALX Oncology Holdings Inc. 3,080,901